Medacta Group Past Earnings Performance
Past criteria checks 3/6
Medacta Group has been growing earnings at an average annual rate of 18.1%, while the Medical Equipment industry saw earnings growing at 10.6% annually. Revenues have been growing at an average rate of 14% per year. Medacta Group's return on equity is 16.3%, and it has net margins of 10.3%.
Key information
18.1%
Earnings growth rate
20.5%
EPS growth rate
| Medical Equipment Industry Growth | 11.1% |
| Revenue growth rate | 14.0% |
| Return on equity | 16.3% |
| Net Margin | 10.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
The Price Is Right For Medacta Group SA (VTX:MOVE)
Nov 22
Is Medacta Group (VTX:MOVE) A Risky Investment?
Oct 14Medacta Group SA (VTX:MOVE) Shares Could Be 32% Above Their Intrinsic Value Estimate
Sep 06What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?
Aug 21Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return
Aug 06Medacta Group SA's (VTX:MOVE) P/E Still Appears To Be Reasonable
Jun 20We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year
May 01Medacta Group (VTX:MOVE) Has A Pretty Healthy Balance Sheet
Apr 17Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?
Mar 29Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?
Feb 22Medacta Group (VTX:MOVE) Will Be Hoping To Turn Its Returns On Capital Around
Feb 07Getting In Cheap On Medacta Group SA (VTX:MOVE) Might Be Difficult
Dec 18Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)
Dec 04Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?
Nov 15Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)
Oct 30If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity
Oct 17Is Medacta Group (VTX:MOVE) Using Too Much Debt?
Sep 29Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)
Aug 11Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?
Jul 27Be Wary Of Medacta Group (VTX:MOVE) And Its Returns On Capital
Jul 03At CHF117, Is It Time To Put Medacta Group SA (VTX:MOVE) On Your Watch List?
Apr 28Is Medacta Group (VTX:MOVE) A Risky Investment?
Apr 08Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?
Dec 25Capital Allocation Trends At Medacta Group (VTX:MOVE) Aren't Ideal
Dec 09Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?
Nov 09Why Medacta Group SA (VTX:MOVE) Could Be Worth Watching
Sep 16The Returns On Capital At Medacta Group (VTX:MOVE) Don't Inspire Confidence
Aug 20Here's Why Medacta Group (VTX:MOVE) Has Caught The Eye Of Investors
Jul 02Should You Think About Buying Medacta Group SA (VTX:MOVE) Now?
May 28Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return
May 12These 4 Measures Indicate That Medacta Group (VTX:MOVE) Is Using Debt Reasonably Well
Mar 31Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?
Mar 17Capital Investments At Medacta Group (VTX:MOVE) Point To A Promising Future
Feb 07Should You Investigate Medacta Group SA (VTX:MOVE) At CHF133?
Dec 10Medacta Group (VTX:MOVE) Knows How To Allocate Capital
Nov 05Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly
Sep 30Is It Too Late To Consider Buying Medacta Group SA (VTX:MOVE)?
Aug 26Medacta Group (VTX:MOVE) May Have Issues Allocating Its Capital
Jul 20Should You Investigate Medacta Group SA (VTX:MOVE) At CHF119?
May 19We Think Medacta Group (VTX:MOVE) Can Stay On Top Of Its Debt
Apr 05What You Need To Know About Medacta Group SA's (VTX:MOVE) Investor Composition
Mar 02Is Medacta Group SA's (VTX:MOVE) 7.6% ROE Better Than Average?
Feb 02The Medacta Group (VTX:MOVE) Share Price Has Gained 24% And Shareholders Are Hoping For More
Jan 12
Returns On Capital At Medacta Group (VTX:MOVE) Paint An Interesting Picture
Dec 21Should You Use Medacta Group's (VTX:MOVE) Statutory Earnings To Analyse It?
Dec 03Revenue & Expenses Breakdown
How Medacta Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 544 | 56 | 271 | 20 |
| 31 Mar 24 | 528 | 52 | 262 | 19 |
| 31 Dec 23 | 511 | 47 | 252 | 19 |
| 30 Sep 23 | 496 | 49 | 245 | 17 |
| 30 Jun 23 | 481 | 50 | 237 | 17 |
| 31 Mar 23 | 459 | 48 | 228 | 16 |
| 31 Dec 22 | 437 | 46 | 220 | 15 |
| 30 Sep 22 | 417 | 47 | 212 | 14 |
| 30 Jun 22 | 397 | 47 | 203 | 14 |
| 31 Mar 22 | 380 | 49 | 193 | 12 |
| 31 Dec 21 | 363 | 52 | 182 | 11 |
| 30 Sep 21 | 354 | 54 | 173 | 10 |
| 30 Jun 21 | 345 | 57 | 164 | 8 |
| 31 Mar 21 | 324 | 47 | 160 | 7 |
| 31 Dec 20 | 302 | 37 | 155 | 7 |
| 30 Sep 20 | 298 | 24 | 166 | 7 |
| 30 Jun 20 | 294 | 10 | 177 | 7 |
| 31 Mar 20 | 302 | 11 | 177 | 8 |
| 31 Dec 19 | 311 | 12 | 176 | 8 |
| 30 Sep 19 | 301 | 22 | 162 | 6 |
| 30 Jun 19 | 291 | 33 | 147 | 5 |
| 31 Mar 19 | 282 | 39 | 143 | 5 |
| 31 Dec 18 | 273 | 46 | 139 | 4 |
| 31 Dec 17 | 245 | 33 | 129 | 3 |
| 31 Dec 16 | 219 | 39 | 113 | 3 |
Quality Earnings: MOVE has high quality earnings.
Growing Profit Margin: MOVE's current net profit margins (10.3%) are lower than last year (10.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MOVE's earnings have grown by 18.1% per year over the past 5 years.
Accelerating Growth: MOVE's earnings growth over the past year (13%) is below its 5-year average (18.1% per year).
Earnings vs Industry: MOVE earnings growth over the past year (13%) exceeded the Medical Equipment industry -1.6%.
Return on Equity
High ROE: MOVE's Return on Equity (16.3%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 04:26 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Medacta Group SA is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Samuel England | Berenberg |
| Christoph Gretler | Credit Suisse |
| David Adlington | J.P. Morgan |